The Cogstate Blog

Gather insights and guidance from the experts in cognitive measurement.

Research Shows Exercise Has Positive Effects on Cognition in Veterans with Depression and BDNF Val66Met Mutation

Research Shows Exercise Has Positive Effects on Cognition in Veterans with Depression and BDNF Val66Met Mutation

A recent study, published in the American Journal of Geriatric Psychiatry, compared the cognitive health of veterans with and without depression alongside their reported level of physical activity and the presence of a variation to a genetic protein known to improve brain plasticity. The study data was gathered from 1,386 U.S. military veterans over the age of 50; each took a web-based survey that included the Cogstate Brief Battery.

September 21, 2020
Study Links Repetitive Head Impacts and Traumatic Brain Injury with Depression and Cognitive Dysfunction

Study Links Repetitive Head Impacts and Traumatic Brain Injury with Depression and Cognitive Dysfunction

New research has reinforced the direct relationship between repetitive head impacts, traumatic brain injury and neurological dysfunction later in life. While a logical link exists, this most recent study provides insight into not only cognitive challenges, like working memory, processing speed, learning and reaction time, but also the onset of depression as a result of experience with contact sports, physical abuse or military service.

August 12, 2020
A4 Study Baseline Data Show C3 Computerized Battery has Potential as Proxy for Paper and Pencil Measures in AD Prevention Trials

A4 Study Baseline Data Show C3 Computerized Battery has Potential as Proxy for Paper and Pencil Measures in AD Prevention Trials

Results from the A4 study baseline assessments have identified that the Computerized Cognitive Composite (C3) battery has potential to serve as a proxy for paper and pencil measures in AD prevention trials. Cogstate’s CSO sat down with Dr. Kate Papp, the lead author of a recent publication showcasing C3 data.

July 10, 2020
AHRQ Systematic Review Classifies Cogstate Cognitive Tests as Highly Sensitive and Specific in Distinguishing Alzheimer’s Disease

AHRQ Systematic Review Classifies Cogstate Cognitive Tests as Highly Sensitive and Specific in Distinguishing Alzheimer’s Disease

A recent review of the cognitive tests available for identifying impairment related to Alzheimer’s disease and its very early stages ranked both the Cogstate Brief Battery (CBB) and the Cogstate International Shopping List Test in the highest bracket for sensitivity and specificity at distinguishing CATD from normal cognition.

May 18, 2020
Study Shows Scopolamine Challenge Test May be a Viable Screening Tool for Aβ-related Cognitive Decline in Preclinical Alzheimer’s Disease

Study Shows Scopolamine Challenge Test May be a Viable Screening Tool for Aβ-related Cognitive Decline in Preclinical Alzheimer’s Disease

While PET scanning will remain important, the scopolamine challenge test (SCT) may offer another method for understanding early AD related changes in people at risk for the disease.

April 15, 2020
Cogstate Computerized Cognitive Testing Receives High Patient Ratings in Diverse Primary Care Settings

Cogstate Computerized Cognitive Testing Receives High Patient Ratings in Diverse Primary Care Settings

Early detection of cognitive impairment in adults is important in planning care for Alzheimer’s Disease. Computerized assessment of cognition has the potential to be leveraged in mainstream primary care settings to efficiently and accurately test millions. Read the research results from SUNY.

March 5, 2020
Soccer Players Who Carry APOE ε4 Variant at Greater Risk from Frequent Heading

Soccer Players Who Carry APOE ε4 Variant at Greater Risk from Frequent Heading

JAMA Neurology published data from a recent study showing soccer players who head the ball more frequently experience episodic memory loss, as demonstrated by lower scores on the Cogstate International Shopping List Delayed Recall (ISRL) test.

February 12, 2020
Cogstate Celebrates 20 Years of Advancing Brain Health Assessment

Cogstate Celebrates 20 Years of Advancing Brain Health Assessment

Martyn Myer AO, Cogstate Chairman, reflects on the history of the company and neuroscience research in Australia.

December 12, 2019
Study Used Cogstate ISLT to Examine the Impact of Cannabis Use on Learning and Memory Function in Young Adults

Study Used Cogstate ISLT to Examine the Impact of Cannabis Use on Learning and Memory Function in Young Adults

Chosen by the researchers for its reliability across language translations and its validity for measuring verbal memory, the Cogstate ISLT assesses immediate and delayed recall of a 12-item list. Read how the ISLT was used by a multi-university team to study the impact of cannabis.

June 2, 2019
Review of Recent FDA Draft Guidance for Rare Disease Clinical Trials

Review of Recent FDA Draft Guidance for Rare Disease Clinical Trials

Dr. Pam Ventola reviews two recent FDA draft guidances for rare disease drug development in this video. Learn about the need for indication-specific outcomes, as well as how to get the most from natural history studies to determine acceptability/feasibility of endpoints and inform future trial designs.

April 22, 2019

How can we help you optimize the measurement of brain health?

Please fill out the form to get in touch